David A. Siegel Pmv Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 751,200 shares of PMVP stock, worth $1.07 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
751,200
Previous 493,500
52.22%
Holding current value
$1.07 Million
Previous $799,000
40.05%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PMVP
# of Institutions
84Shares Held
41.7MCall Options Held
3.1KPut Options Held
1.7K-
Orbimed Advisors LLC San Diego, CA6.48MShares$9.19 Million0.23% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO3.65MShares$5.18 Million0.08% of portfolio
-
Sio Capital Management, LLC New York, NY3.21MShares$4.56 Million2.53% of portfolio
-
Euclidean Capital LLC New York, NY2.63MShares$3.73 Million0.43% of portfolio
-
Alkeon Capital Management LLC New York, NY2.34MShares$3.33 Million0.01% of portfolio
About PMV Pharmaceuticals, Inc.
- Ticker PMVP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,622,600
- Market Cap $64.8M
- Description
- PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...